Pfizer rallied 8.08% to Rs 4,755.25 after the company said its board declared a special dividend of Rs 320 per equity share for the financial year ended 31 March 2020.
The record date is fixed on 8 May 2020. The stock offers a dividend yield of 6.73% at the current market price. The announcement was made during trading hours today, 27 April 2020.
The Indian drug maker’s standalone net profit rose 5.4% to Rs 139.06 crore on a 4.7% increase in net sales to Rs 538.18 crore in Q3 December 2019 over Q3 December 2018.
Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.
COVID-19, is a new virus with no vaccines or pills, which can change the current threat to an amazing opportunity, for companies like Pfizer.
Pfizer’s global parent has received a German regulatory authority, the Paul-Ehrlich-Institut, approval for Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection.
BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany and is part of a global development program.
Pfizer and BioNTech will also conduct trials for BNT162 in the United States upon regulatory approval, which is expected shortly.
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.